PIM-1 inhibitors: anyone participating in this trial?

Hello BMT community - anyone participating in this trial:
PIM-1 inhibitors are targeted therapeutic agents designed to block the activity of PIM-1 kinases, which are enzymes that promote cell survival and block apoptosis (cell death) in many cancers. These inhibitors, often small molecules, show potential in treating solid tumors and hematological malignancies by forcing cancer cells to die.

Key Aspects of PIM-1 Inhibitors

Mechanism of Action: They inhibit the kinase activity of the PIM-1 protein, a "weak oncogene" that is overexpressed in numerous cancers, including prostate cancer, lymphoma, and leukemia.

Therapeutic Potential: By reducing tumor volume, inhibiting cancer cell proliferation, and modulating the inflammatory environment, they act as promising anti-cancer therapies.

Overcoming Resistance: PIM-1 inhibitors are being studied for their ability to combat resistance to other therapies, such as anti-angiogenic agents and HER2 inhibitors in breast cancer.

Clinical Development: Several inhibitors are in preclinical or early-phase clinical trials, such as TP-3654 (SGI-9481) (a pan-PIM inhibitor), AZD1208, and PIM447.

Targeted Cancers and Diseases

Prostate and Breast Cancer: PIM-1 is often overexpressed in these, making them primary targets.Myelofibrosis: A potential therapeutic approach for managing symptom burden and reducing spleen volume.Other Potential Uses: Researchers are exploring their use in treating Alzheimer's disease.

Commonly Discussed Inhibitors
- Nuvisertib (SEL24/LY206894): Evaluated for myelofibrosis.
- TP-3654: Known for reducing tumor volume in preclinical trials.
- ETP-45299: A potent and selective inhibitor that suppresses tumor cell lines.

These inhibitors are considered crucial for next-generation personalized medicine in oncology, particularly when used in combination with other treatments.